LEP and metabolic dysfunction-associated steatotic liver disease: Previously, leptin antagonists have been demonstrated to be beneficial in some mice models of disorders associated with metabolic syndrome or hyperleptinemia such as non-alcoholic fatty liver disease [36] or chronic kidney disease-induced lean body mass loss (Gertler A et al, unpublished observation).